Insider Jeffrey George Buys 22,100 Shares of LENZ
Jeffrey George and other insiders bought shares of LENZ on June 15, 2026.
Key Points
- On June 15, 2026, insider Jeffrey George bought 22,100 shares of LENZ.
- Shares of LENZ traded near $6.77, with multiple funds adjusting their positions.
- Analysts from Citigroup and HC Wainwright maintained buy ratings on LENZ.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Insider Jeffrey George made a notable transaction by purchasing 22,100 shares of LENZ on June 15, 2026. This move aligns with purchases by several other insiders on the same day, all acquiring the same amount of shares.
Other Institutional Activity in LENZ
Versant Venture Management, LLC significantly increased its holdings in LENZ, adding 2,656,888 shares to reach a total of 5,313,776 shares, valued at about $48.6 million. BlackRock, Inc. also boosted its stake by 284,817 shares, ending with 1,976,823 shares worth approximately $18.1 million. Meanwhile, FMR LLC trimmed its position by 104,934 shares, holding 3,597,784 shares valued at $32.9 million.
LENZ Therapeutics, Inc. Stock Up 32.5%
Shares of LENZ traded near $6.77. The stock has seen various institutional activities, suggesting ongoing interest in its performance. However, specific financial ratios and metrics such as market cap, P/E ratio, and beta were not available.
Insider Buying and Selling at LENZ Therapeutics, Inc.
On June 15, 2026, several insiders, including Jeffrey George, Zachary Scheiner, Frederic Guerard, James McCollum, Shelley Thunen, and Kimberlee Drapkin, each bought 22,100 shares of LENZ. These were not pre-planned transactions, indicating a possible vote of confidence in the company's prospects.
Analysts Set New Price Targets
Analysts have been active with LENZ, maintaining a generally positive outlook. On May 13, 2026, Citigroup maintained its buy rating with a price target of $20. HC Wainwright & Co. also maintained a buy rating with a higher target of $38 on May 12, 2026. However, Piper Sandler downgraded the stock to a hold with a $12 target on the same day.
Bottom Line
The recent insider purchases at LENZ, including Jeffrey George's acquisition, highlight a potential positive sentiment among company insiders. Institutional investors have also been adjusting their positions, reflecting varied strategies. Analyst ratings remain mostly positive, though some caution is evident. As always, these insights are based on past transactions and do not necessarily predict future performance.
Get LENZ Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LENZ, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.